BR112018012616A2 - formulação galênica que compreende um fármaco tópico - Google Patents

formulação galênica que compreende um fármaco tópico

Info

Publication number
BR112018012616A2
BR112018012616A2 BR112018012616A BR112018012616A BR112018012616A2 BR 112018012616 A2 BR112018012616 A2 BR 112018012616A2 BR 112018012616 A BR112018012616 A BR 112018012616A BR 112018012616 A BR112018012616 A BR 112018012616A BR 112018012616 A2 BR112018012616 A2 BR 112018012616A2
Authority
BR
Brazil
Prior art keywords
topical drug
galenic formulation
relates
drug
galenic
Prior art date
Application number
BR112018012616A
Other languages
English (en)
Inventor
Cantina Catherine
Haug Claire
Rault Isabelle
Enikö Grubesa Melinda
Keller Michael
Fernandes Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112018012616A2 publication Critical patent/BR112018012616A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a composições farmacêuticas, que compreendem um fármaco para a administração tópica, por exemplo, um modulador tlr7. mais especificamente, a invenção refere-se a uma composição farmacêutica que compreende um derivado de benzo[f][1,7]naftiridina.
BR112018012616A 2015-01-21 2016-01-21 formulação galênica que compreende um fármaco tópico BR112018012616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15151973 2015-01-21
PCT/IB2016/050293 WO2016116886A1 (en) 2015-01-21 2016-01-21 Galenic formulation comprising a topical drug

Publications (1)

Publication Number Publication Date
BR112018012616A2 true BR112018012616A2 (pt) 2018-12-04

Family

ID=52394939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012616A BR112018012616A2 (pt) 2015-01-21 2016-01-21 formulação galênica que compreende um fármaco tópico

Country Status (17)

Country Link
US (1) US20190021989A1 (pt)
EP (1) EP3405210A1 (pt)
JP (1) JP2019502735A (pt)
KR (1) KR20180097177A (pt)
CN (1) CN108601728A (pt)
AR (1) AR103466A1 (pt)
AU (1) AU2016209917B2 (pt)
BR (1) BR112018012616A2 (pt)
CA (1) CA3010208A1 (pt)
CL (1) CL2018001797A1 (pt)
HK (1) HK1256152A1 (pt)
IL (1) IL260119A (pt)
MX (1) MX2018008938A (pt)
PH (1) PH12018501487A1 (pt)
RU (1) RU2699022C1 (pt)
TW (1) TW201630606A (pt)
WO (1) WO2016116886A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209718A1 (en) * 2021-02-25 2022-09-01 Gary Michael PEKOE Composition for treatment of topical dermatological bacterial skin conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526936T2 (de) * 1994-04-13 2003-02-20 Romark Lab Lc Benzamide-derivate, zubereitungen die sie erhalten und ihre anwendung
US20040023870A1 (en) * 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AU2009222105B2 (en) * 2008-03-03 2012-05-17 Novartis Ag Compounds and compositions as TLR activity modulators
WO2010124175A1 (en) * 2009-04-24 2010-10-28 Johnson & Johnson Consumer Companies, Inc. Stable topical compositions for 1,2,4-thiadiazole derivatives
AU2010274097B2 (en) * 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
CA2796314A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
WO2013088379A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited A topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
WO2013162828A1 (en) * 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof

Also Published As

Publication number Publication date
RU2699022C1 (ru) 2019-09-03
AU2016209917B2 (en) 2019-07-11
AU2016209917A1 (en) 2018-07-12
CA3010208A1 (en) 2016-07-28
CL2018001797A1 (es) 2018-08-17
IL260119A (en) 2018-07-31
PH12018501487A1 (en) 2019-03-25
JP2019502735A (ja) 2019-01-31
EP3405210A1 (en) 2018-11-28
KR20180097177A (ko) 2018-08-30
HK1256152A1 (zh) 2019-09-13
US20190021989A1 (en) 2019-01-24
WO2016116886A1 (en) 2016-07-28
AR103466A1 (es) 2017-05-10
TW201630606A (zh) 2016-09-01
MX2018008938A (es) 2018-09-03
CN108601728A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CL2020000747A1 (es) Formulaciones de niraparib.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
ECSP14013275A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
EP3613419A4 (en) PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
WO2016112875A3 (zh) 二联苯衍生物及其应用
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
EP3318259A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
GT201400115A (es) Combinación farmacéutica antineurítica y composición
MX2019015869A (es) Nuevas formulaciones orales de belinostat.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements